Paid Clinical Trials Tucson
Discover 486 paid clinical trials in Tucson, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
VNX001Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Sponsor:
Vaneltix Pharma, Inc.
Location:
Code:
NCT06394830
Conditions
Interstitial Cystitis
Bladder Pain Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
VNX001
Selinexor, Pomalidomide, Dexamethasone, ElotuzumabA Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Sponsor:
Stichting European Myeloma Network
Location:
Code:
NCT05028348
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Elotuzumab
Pomalidomide
Dexamethasone Oral
Luveltamab Tazevibulin vs. IC ChemotherapyREFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sponsor:
Sutro Biopharma, Inc.
Location:
Code:
NCT05870748
Conditions
Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Luveltamab tazevibulin
Pegfilgrastim
Gemcitabine
Paclitaxel
Pegylated liposomal doxorubicin
NanO2™ & RadiationA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Sponsor:
NuvOx LLC
Location:
Code:
NCT03862430
Conditions
Glioblastoma Multiforme
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NanO2TM
Placebo Saline Infusion
STM-416A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Sponsor:
SURGE Therapeutics
Location:
Code:
NCT05710848
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
STM-416
Investigational Agents & PembrolizumabA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT05319730
Conditions
Esophageal Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Paclitaxel
Irinotecan
Pembrolizumab
MK-4830
Lenvatinib
Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05455320
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Talquetamab
Daratumumab
Pomalidomide
Dexamethasone
Thrombin Receptor AntagonistExcellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Sponsor:
North Texas Veterans Healthcare System
Location:
Code:
NCT02660866
Conditions
Peripheral Arterial Disease
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo + background APT + SMT
Vorapaxar 2.08 mg/d + background APT + SMT.
Epcoritamab & Anti-NeoplasticsA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Sponsor:
Genmab
Location:
Code:
NCT05283720
Conditions
Non-Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Epcoritamab
Lenalidomide
Ibrutinib
Rituximab
Cyclophosphamide